Children with Diabetes partners with ISPAD and the JENIOUS Group to promote research projects aimed at improving care today, expecting a cure tomorrow. The CwD-JENIOUS Award supports researchers in developing their own diabetes research initiatives, providing extensive networking opportunities to make their projects feasible, enhancing visibility, and fostering potential international collaborations.
Read more about this parternship here and stay tuned to discover more about the new JENIOUS-CwD Research Projects! https://childrenwithdiabetes.com/cwd-news/cwd-jenious-award/
JENIOUS-CwD project - Guideline for authors
Children with Diabetes and the JENIOUS Leadership team are glad to announce the call for the JENIOUS-CwD project with the motto “care today, expecting a cure tomorrow”.
Please prepare your proposal using this template https://www.ispad.org/asset/BF13EB6A%2DF3A8%2D4CF8%2D891AFF25B2962C91/ with the following information:
Author(s) and contact details
Project title, brief background, objective, methods, feasibility, expected results, indication if there are any costs (if yes - the source for covering them). We ask you to submit it to [email protected] latest by Friday July 25th, 2025.
The JENIOUS Leadership and CwD representative will evaluate projects according to the following criteria:
Relevance
Innovation
Methodology
Feasibility
Impact
Authors of the best two project proposals will present in the JENIOUS session at the ISPAD 2025 Conference (in person or virtually). During this session, Children with Diabetes will award the best project proposal with the JENIOUS-CwD Prize.
The award is an invitation from CwD to their annual conference “Friends For Life” in 2026 and mentorship for the program.
We highlight that the JENIOUS will offer all the networking opportunities to make your research project feasible and to give visibility to it, but we cannot offer any funds for it. If you have an outstanding project idea aligned with the theme, submit your proposal!
Created: 26 Jun 2025 06:06:22 PM
Please accept {{cookieConsents}} cookies to view this content
All Replies (0)
There are no replies to this discussion.